Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Securities Fraud Class Action Suits Could Grow After Amgen’s Supreme Court Loss

This article was originally published in The Pink Sheet Daily

Executive Summary

Supreme Court rules 6-3 that plaintiffs do not need to prove that a company’s misrepresentations were material at the class certification stage; investors allege Amgen misrepresented the safety of Aranesp and Epogen.

You may also be interested in...



Judge Gorsuch Could Be Pharma Ally In FDA Disputes

Supreme Court nominee's opposition to deference for administrative agencies could help biopharma industry in its battle over off-label communications if the issue ever goes before the court; he also supports securities litigation reform.

Amgen Stock Drop Suit Booted By Supreme Court, But Not On Principle

Former employees might not be able to sue Amgen regarding insider knowledge of Aranesp problems, but other firms could still face similar ERISA suits – and Amgen itself is still fighting litigation from disgruntled investors.

Pharma Securities Fraud Worries Reduced In Supreme Court Omnicare Ruling

High court finds that a corporation’s statement of opinion is not actionable unless company did not sincerely believe it; ruling makes it harder for plaintiffs to file stock fraud claims.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel